SCHEMBL14285641

SCHEMBL14285641

Oc1ccc(/C=N/N=C/c2ccc(O)cc2O)c(O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.62
MEN1 O00255 6/20 0.58
KMT2A Q03164 6/20 0.58
ALPL P05186 1/20 0.58
POLB P06746 1/20 0.58
ALPI P09923 1/20 0.58
ALPG P10696 1/20 0.58
EIF4H Q15056 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
AMY1A P0DUB6 1/20 0.56
MAPT P10636 5/20 0.55
GAA P10253 3/20 0.55
NPC1 O15118 2/20 0.55
ALDH1A1 P00352 2/20 0.55
KDM4E B2RXH2 2/20 0.53
NTRK1 P04629 1/20 0.51
RAB9A P51151 1/20 0.50
SYNJ2 O15056 1/20 0.50
TTR P02766 1/20 0.50
CYP1A1 P04798 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30382267 1.00 HSP90AA1 (0.62) HSP90AA1MEN1KMT2AALPLPOLB
SCHEMBL5162147 0.84 MEN1 (0.56) HSP90AA1MEN1KMT2AALPLPOLB
SCHEMBL4050154 0.84 MEN1 (0.56) HSP90AA1MEN1KMT2AALPLPOLB
SCHEMBL1156333 0.84 MEN1 (0.56) HSP90AA1MEN1KMT2AALPLPOLB
SCHEMBL23837627 0.82 MEN1 (0.55) HSP90AA1MEN1KMT2AALPLPOLB
SCHEMBL14223791 0.82 MEN1 (0.55) HSP90AA1MEN1KMT2AALPLPOLB
SCHEMBL2700313 0.82 MEN1 (0.55) HSP90AA1MEN1KMT2AALPLPOLB
SCHEMBL2313381 0.82 MEN1 (0.55) HSP90AA1MEN1KMT2AALPLPOLB
SCHEMBL23837601 0.82 MEN1 (0.55) HSP90AA1MEN1KMT2AALPLPOLB
SCHEMBL11856720 0.81 AMY1A (0.56) HSP90AA1MEN1KMT2AALPLPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150192589-A1 METHOD USING FLUORESCENT TURN-ON PROBES FOR CELL-SPECIFIC DETECTION AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-07-09 US disclosed
US-20150192589-A1 METHOD USING FLUORESCENT TURN-ON PROBES FOR CELL-SPECIFIC DETECTION AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-07-09 US disclosed
US-20080015194-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph (US) 2008-01-17 US disclosed
US-20080015194-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph (US) 2008-01-17 US disclosed
WO-2007087266-A2 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT ERRICO JOSEPH P (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015194-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT CD74, HAVCR2, CD47 HSP90AA1 161/4885MEN1 4461/4885KMT2A 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.